| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Adrenergic, alpha | 50 | 1996 | 146 | 2.490 |
Why?
|
| Muscle, Smooth, Vascular | 35 | 2002 | 1492 | 1.860 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 13 | 2007 | 42 | 1.750 |
Why?
|
| Receptors, Adrenergic, beta | 34 | 2002 | 242 | 1.300 |
Why?
|
| Vasodilation | 26 | 2000 | 962 | 1.230 |
Why?
|
| Cyclic AMP | 38 | 2002 | 1463 | 1.120 |
Why?
|
| Receptors, Adrenergic | 26 | 2000 | 155 | 1.050 |
Why?
|
| Isoproterenol | 39 | 2002 | 397 | 0.910 |
Why?
|
| Veins | 24 | 2007 | 767 | 0.860 |
Why?
|
| Hand | 24 | 2007 | 902 | 0.840 |
Why?
|
| Adrenergic alpha-Agonists | 12 | 1999 | 177 | 0.820 |
Why?
|
| Phenylephrine | 26 | 2007 | 293 | 0.800 |
Why?
|
| Pheochromocytoma | 15 | 1991 | 328 | 0.780 |
Why?
|
| Norepinephrine | 22 | 2003 | 898 | 0.680 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 4 | 2004 | 69 | 0.670 |
Why?
|
| Lipolysis | 14 | 1994 | 211 | 0.620 |
Why?
|
| Bradykinin | 15 | 2007 | 208 | 0.620 |
Why?
|
| Aging | 26 | 1996 | 8699 | 0.550 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 4 | 2004 | 502 | 0.530 |
Why?
|
| Adrenergic alpha-Antagonists | 11 | 2000 | 174 | 0.530 |
Why?
|
| Adrenal Gland Neoplasms | 12 | 1991 | 732 | 0.510 |
Why?
|
| Rats, Inbred Strains | 31 | 1992 | 2088 | 0.510 |
Why?
|
| Hypertension | 34 | 2007 | 8529 | 0.510 |
Why?
|
| Nitric Oxide | 12 | 2007 | 2135 | 0.490 |
Why?
|
| Genes, fos | 5 | 1999 | 175 | 0.460 |
Why?
|
| Prazosin | 20 | 1996 | 95 | 0.420 |
Why?
|
| Alprostadil | 13 | 1996 | 86 | 0.420 |
Why?
|
| Rats | 72 | 1999 | 23717 | 0.410 |
Why?
|
| Angiotensin II | 5 | 2002 | 849 | 0.390 |
Why?
|
| Fatty Acids, Nonesterified | 8 | 1995 | 393 | 0.370 |
Why?
|
| Epinephrine | 18 | 1993 | 792 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 39 | 2007 | 10754 | 0.360 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 5 | 1999 | 489 | 0.350 |
Why?
|
| Muscle Contraction | 12 | 1995 | 1200 | 0.350 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 3 | 1999 | 18 | 0.340 |
Why?
|
| Receptors, Muscarinic | 4 | 1996 | 157 | 0.340 |
Why?
|
| Tetralones | 5 | 1988 | 8 | 0.330 |
Why?
|
| Doxazosin | 2 | 1999 | 18 | 0.330 |
Why?
|
| Vasoconstriction | 13 | 2000 | 592 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2004 | 584 | 0.320 |
Why?
|
| Protein Kinase C | 8 | 1998 | 1202 | 0.310 |
Why?
|
| Aorta | 13 | 1996 | 2041 | 0.310 |
Why?
|
| Nitroprusside | 5 | 2000 | 272 | 0.300 |
Why?
|
| Decision Support Systems, Clinical | 7 | 2006 | 1167 | 0.290 |
Why?
|
| Adipose Tissue | 18 | 1991 | 3309 | 0.290 |
Why?
|
| Transcription, Genetic | 8 | 2000 | 7583 | 0.290 |
Why?
|
| Gene Expression Regulation | 9 | 1999 | 11874 | 0.290 |
Why?
|
| Muscle Relaxation | 7 | 1992 | 138 | 0.280 |
Why?
|
| Vascular Resistance | 3 | 2007 | 930 | 0.270 |
Why?
|
| Cell Division | 5 | 2002 | 4457 | 0.270 |
Why?
|
| Catecholamines | 14 | 1994 | 387 | 0.260 |
Why?
|
| Carbachol | 7 | 1996 | 223 | 0.250 |
Why?
|
| Therapy, Computer-Assisted | 3 | 2006 | 266 | 0.250 |
Why?
|
| Proto-Oncogenes | 2 | 1996 | 321 | 0.250 |
Why?
|
| Receptors, Histamine H2 | 2 | 1995 | 18 | 0.250 |
Why?
|
| Receptors, Histamine H1 | 2 | 1995 | 19 | 0.250 |
Why?
|
| Guideline Adherence | 5 | 2006 | 2218 | 0.240 |
Why?
|
| Fear | 2 | 2004 | 1477 | 0.240 |
Why?
|
| Nitroglycerin | 10 | 2000 | 329 | 0.240 |
Why?
|
| Adenosine | 5 | 1993 | 805 | 0.240 |
Why?
|
| Virulence Factors, Bordetella | 5 | 1999 | 154 | 0.230 |
Why?
|
| Pertussis Toxin | 5 | 1999 | 176 | 0.230 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 4 | 1999 | 485 | 0.220 |
Why?
|
| GTP-Binding Proteins | 6 | 1999 | 949 | 0.220 |
Why?
|
| omega-N-Methylarginine | 4 | 1999 | 108 | 0.210 |
Why?
|
| Animals | 109 | 2004 | 168201 | 0.210 |
Why?
|
| Erythropoietin | 1 | 2007 | 719 | 0.210 |
Why?
|
| Aorta, Thoracic | 8 | 1996 | 1096 | 0.200 |
Why?
|
| Phenylisopropyladenosine | 5 | 1989 | 14 | 0.200 |
Why?
|
| Mitogens | 2 | 1999 | 229 | 0.200 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 318 | 0.190 |
Why?
|
| Enzyme Activation | 10 | 1999 | 3591 | 0.190 |
Why?
|
| Isoenzymes | 3 | 2002 | 1687 | 0.190 |
Why?
|
| Locus Coeruleus | 1 | 2003 | 230 | 0.190 |
Why?
|
| RNA, Messenger | 15 | 2002 | 12758 | 0.190 |
Why?
|
| Receptors, Prostaglandin | 3 | 1992 | 53 | 0.190 |
Why?
|
| Vasodilator Agents | 7 | 2007 | 973 | 0.190 |
Why?
|
| Calcium Channel Blockers | 3 | 1995 | 694 | 0.190 |
Why?
|
| Knowledge Bases | 2 | 2015 | 97 | 0.190 |
Why?
|
| Arginine | 5 | 1999 | 933 | 0.190 |
Why?
|
| Conditioning, Classical | 1 | 2004 | 368 | 0.190 |
Why?
|
| Ribosomal Protein S6 Kinases | 2 | 1998 | 203 | 0.180 |
Why?
|
| Phosphorylases | 4 | 1989 | 17 | 0.180 |
Why?
|
| Receptors, Purinergic | 4 | 1989 | 66 | 0.180 |
Why?
|
| Insulin | 12 | 1996 | 6593 | 0.180 |
Why?
|
| Radioligand Assay | 13 | 1986 | 366 | 0.180 |
Why?
|
| Histamine | 5 | 1997 | 499 | 0.180 |
Why?
|
| Antihypertensive Agents | 4 | 2007 | 2016 | 0.180 |
Why?
|
| Blood Pressure | 23 | 2000 | 8472 | 0.170 |
Why?
|
| Potassium | 3 | 1995 | 1311 | 0.170 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 1999 | 2864 | 0.170 |
Why?
|
| Sympathetic Nervous System | 4 | 1993 | 519 | 0.170 |
Why?
|
| Hybrid Cells | 5 | 1995 | 422 | 0.170 |
Why?
|
| Phenethylamines | 5 | 1988 | 95 | 0.170 |
Why?
|
| Toxicity Tests | 1 | 2000 | 114 | 0.170 |
Why?
|
| Propranolol | 11 | 1996 | 490 | 0.160 |
Why?
|
| Yohimbine | 14 | 1987 | 62 | 0.160 |
Why?
|
| omega-Conotoxins | 3 | 1995 | 18 | 0.160 |
Why?
|
| Protein Kinases | 6 | 2000 | 1606 | 0.160 |
Why?
|
| Fructose | 3 | 1990 | 288 | 0.160 |
Why?
|
| Adenylate Cyclase Toxin | 3 | 1990 | 25 | 0.160 |
Why?
|
| Neuroblastoma | 7 | 1995 | 1248 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 3 | 1999 | 908 | 0.160 |
Why?
|
| Niacin | 3 | 1989 | 118 | 0.160 |
Why?
|
| Pharmacokinetics | 2 | 1989 | 86 | 0.160 |
Why?
|
| Endothelium, Vascular | 7 | 2000 | 4433 | 0.160 |
Why?
|
| Cardiomyopathies | 5 | 1993 | 1948 | 0.160 |
Why?
|
| Muscarinic Agonists | 2 | 1996 | 91 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 13 | 1996 | 8166 | 0.160 |
Why?
|
| Cycloheximide | 3 | 1993 | 343 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 6 | 2002 | 346 | 0.160 |
Why?
|
| Dihydroergotoxine | 9 | 1981 | 21 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 11 | 1995 | 6126 | 0.150 |
Why?
|
| Drug Therapy, Computer-Assisted | 3 | 2006 | 197 | 0.150 |
Why?
|
| Memory | 3 | 2004 | 2192 | 0.140 |
Why?
|
| Nifedipine | 3 | 1993 | 221 | 0.140 |
Why?
|
| Calcium | 4 | 1999 | 5717 | 0.140 |
Why?
|
| Binding, Competitive | 17 | 1992 | 1141 | 0.140 |
Why?
|
| Male | 106 | 2007 | 360358 | 0.140 |
Why?
|
| Phosphatidylinositols | 5 | 1994 | 282 | 0.140 |
Why?
|
| Cells, Cultured | 16 | 2002 | 18937 | 0.140 |
Why?
|
| Clonidine | 6 | 1993 | 169 | 0.140 |
Why?
|
| Regional Blood Flow | 7 | 1995 | 1496 | 0.140 |
Why?
|
| Guanylyl Imidodiphosphate | 9 | 1986 | 37 | 0.130 |
Why?
|
| Patient Compliance | 2 | 2007 | 2688 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2005 | 1669 | 0.130 |
Why?
|
| Glycerol | 3 | 1995 | 274 | 0.130 |
Why?
|
| Amygdala | 1 | 2004 | 1353 | 0.130 |
Why?
|
| Triglycerides | 6 | 1993 | 2459 | 0.130 |
Why?
|
| Stimulation, Chemical | 6 | 2002 | 306 | 0.130 |
Why?
|
| Drug Therapy | 2 | 1989 | 503 | 0.130 |
Why?
|
| Pindolol | 8 | 1996 | 34 | 0.130 |
Why?
|
| Kinetics | 16 | 1999 | 6370 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2007 | 2477 | 0.120 |
Why?
|
| Captopril | 2 | 1999 | 265 | 0.120 |
Why?
|
| Narcotics | 1 | 1996 | 335 | 0.120 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1993 | 817 | 0.110 |
Why?
|
| Fibroblasts | 6 | 1999 | 4137 | 0.110 |
Why?
|
| Rabbits | 15 | 1989 | 4770 | 0.110 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 1996 | 397 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2000 | 9417 | 0.110 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1996 | 433 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2004 | 2756 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 1995 | 217 | 0.110 |
Why?
|
| Myocardium | 10 | 1996 | 4724 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 1999 | 1745 | 0.110 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 149 | 0.110 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1992 | 350 | 0.110 |
Why?
|
| Rats, Inbred SHR | 2 | 1990 | 186 | 0.110 |
Why?
|
| Etorphine | 1 | 1993 | 3 | 0.110 |
Why?
|
| Liver | 9 | 1986 | 7512 | 0.110 |
Why?
|
| Recombinant Proteins | 5 | 2007 | 6520 | 0.110 |
Why?
|
| Raynaud Disease | 1 | 1993 | 79 | 0.110 |
Why?
|
| Methylene Blue | 4 | 1994 | 155 | 0.110 |
Why?
|
| Diltiazem | 1 | 1993 | 131 | 0.110 |
Why?
|
| Isosorbide Dinitrate | 1 | 1992 | 34 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 1999 | 2425 | 0.110 |
Why?
|
| Phentolamine | 8 | 1987 | 102 | 0.100 |
Why?
|
| Erythrocyte Membrane | 3 | 1985 | 439 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 7 | 2006 | 7389 | 0.100 |
Why?
|
| Neural Pathways | 1 | 2003 | 3056 | 0.100 |
Why?
|
| Indomethacin | 4 | 1994 | 323 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 6 | 2005 | 1191 | 0.100 |
Why?
|
| 3T3 Cells | 3 | 1999 | 1085 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 1998 | 1755 | 0.100 |
Why?
|
| Blood Glucose | 6 | 1993 | 6390 | 0.100 |
Why?
|
| Mesenteric Arteries | 7 | 1989 | 178 | 0.100 |
Why?
|
| Blood Platelets | 11 | 1983 | 2478 | 0.100 |
Why?
|
| Morphine | 1 | 1996 | 655 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1998 | 1932 | 0.100 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 3 | 1999 | 56 | 0.100 |
Why?
|
| Heart Rate | 11 | 1993 | 4180 | 0.100 |
Why?
|
| Heparin | 1 | 1999 | 1632 | 0.100 |
Why?
|
| Enzyme Inhibitors | 7 | 1999 | 3705 | 0.100 |
Why?
|
| Muscle, Smooth | 2 | 1993 | 927 | 0.100 |
Why?
|
| Receptors, Somatostatin | 1 | 1992 | 136 | 0.100 |
Why?
|
| Humans | 104 | 2015 | 760617 | 0.100 |
Why?
|
| Prostate | 1 | 2000 | 1773 | 0.090 |
Why?
|
| Phosphates | 2 | 1995 | 769 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1988 | 1117 | 0.090 |
Why?
|
| Acetylcysteine | 1 | 1992 | 260 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2000 | 3777 | 0.090 |
Why?
|
| Iodocyanopindolol | 7 | 1988 | 10 | 0.090 |
Why?
|
| Rats, Inbred WKY | 2 | 1990 | 150 | 0.090 |
Why?
|
| Hypercholesterolemia | 2 | 1999 | 1141 | 0.090 |
Why?
|
| Hot Temperature | 1 | 1997 | 1437 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 1996 | 1241 | 0.090 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 3 | 1998 | 221 | 0.090 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 625 | 0.090 |
Why?
|
| Phorbol Esters | 2 | 1992 | 108 | 0.090 |
Why?
|
| Halothane | 2 | 1988 | 200 | 0.090 |
Why?
|
| Gene Expression | 4 | 2000 | 7568 | 0.090 |
Why?
|
| Precipitin Tests | 2 | 2002 | 813 | 0.090 |
Why?
|
| Prostaglandins E | 2 | 1987 | 166 | 0.090 |
Why?
|
| Cimetidine | 3 | 1995 | 76 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 1992 | 392 | 0.080 |
Why?
|
| Vasoconstrictor Agents | 3 | 2007 | 654 | 0.080 |
Why?
|
| Enalaprilat | 2 | 1999 | 10 | 0.080 |
Why?
|
| Atenolol | 3 | 1996 | 99 | 0.080 |
Why?
|
| Iodine Radioisotopes | 5 | 1990 | 1031 | 0.080 |
Why?
|
| Interleukin-1 | 1 | 1993 | 1248 | 0.080 |
Why?
|
| Uterus | 7 | 1981 | 649 | 0.080 |
Why?
|
| Hyperinsulinism | 2 | 1989 | 400 | 0.080 |
Why?
|
| Drug Tolerance | 4 | 1992 | 367 | 0.080 |
Why?
|
| Carbohydrate Metabolism | 1 | 1989 | 262 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 1992 | 642 | 0.080 |
Why?
|
| Cues | 2 | 2004 | 875 | 0.080 |
Why?
|
| Phosphorylation | 4 | 2004 | 8311 | 0.080 |
Why?
|
| Molecular Sequence Data | 8 | 1996 | 17629 | 0.080 |
Why?
|
| Lymphoma | 7 | 1992 | 1899 | 0.080 |
Why?
|
| Ethers, Cyclic | 1 | 1988 | 32 | 0.080 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 1 | 1988 | 32 | 0.080 |
Why?
|
| Sugar Phosphates | 1 | 1987 | 44 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 1995 | 8542 | 0.080 |
Why?
|
| Diabetic Neuropathies | 1 | 1992 | 405 | 0.080 |
Why?
|
| User-Computer Interface | 5 | 2006 | 1397 | 0.080 |
Why?
|
| Lipoproteins | 2 | 1989 | 879 | 0.070 |
Why?
|
| Heart Ventricles | 3 | 1996 | 3796 | 0.070 |
Why?
|
| Patient Care | 1 | 2013 | 621 | 0.070 |
Why?
|
| Cell Cycle | 1 | 1996 | 2930 | 0.070 |
Why?
|
| Inositol Phosphates | 1 | 1987 | 176 | 0.070 |
Why?
|
| Signal Transduction | 8 | 2000 | 23416 | 0.070 |
Why?
|
| Adult | 42 | 2007 | 220969 | 0.070 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 4 | 1990 | 100 | 0.070 |
Why?
|
| Epoxy Compounds | 1 | 1988 | 137 | 0.070 |
Why?
|
| Cricetinae | 5 | 1993 | 2424 | 0.070 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 1986 | 5 | 0.070 |
Why?
|
| Glucose | 4 | 1999 | 4345 | 0.070 |
Why?
|
| Female | 59 | 2007 | 392148 | 0.070 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1994 | 1360 | 0.070 |
Why?
|
| Adipocytes | 1 | 1994 | 1187 | 0.070 |
Why?
|
| Phosphotyrosine | 2 | 1999 | 456 | 0.070 |
Why?
|
| Cyclic GMP | 3 | 1993 | 395 | 0.070 |
Why?
|
| Theophylline | 1 | 1987 | 131 | 0.070 |
Why?
|
| Base Sequence | 5 | 1996 | 12421 | 0.070 |
Why?
|
| Somatostatin | 1 | 1989 | 447 | 0.070 |
Why?
|
| Octreotide | 3 | 1992 | 154 | 0.070 |
Why?
|
| Peptides | 3 | 1995 | 4354 | 0.070 |
Why?
|
| Phenoxybenzamine | 3 | 1995 | 53 | 0.070 |
Why?
|
| Insulin Resistance | 6 | 1989 | 3954 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 2002 | 1545 | 0.070 |
Why?
|
| Drug Interactions | 5 | 2000 | 1415 | 0.070 |
Why?
|
| Cell Nucleus | 3 | 2002 | 2894 | 0.060 |
Why?
|
| Coturnix | 1 | 1985 | 22 | 0.060 |
Why?
|
| Quail | 1 | 1985 | 40 | 0.060 |
Why?
|
| Membrane Fluidity | 1 | 1985 | 68 | 0.060 |
Why?
|
| Cell Line | 7 | 2000 | 15576 | 0.060 |
Why?
|
| Phorbols | 1 | 1985 | 43 | 0.060 |
Why?
|
| Digoxin | 1 | 1987 | 246 | 0.060 |
Why?
|
| Calcium Channels | 3 | 1994 | 620 | 0.060 |
Why?
|
| San Francisco | 1 | 2005 | 162 | 0.060 |
Why?
|
| Receptors, Cholinergic | 1 | 1986 | 244 | 0.060 |
Why?
|
| Physical Exertion | 1 | 1988 | 668 | 0.060 |
Why?
|
| Rats, Inbred F344 | 4 | 1996 | 826 | 0.060 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2007 | 244 | 0.060 |
Why?
|
| Metronidazole | 1 | 1987 | 232 | 0.060 |
Why?
|
| Down-Regulation | 1 | 1992 | 2915 | 0.060 |
Why?
|
| Glioma | 6 | 1995 | 3453 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1987 | 241 | 0.060 |
Why?
|
| Lipid Mobilization | 1 | 1984 | 16 | 0.060 |
Why?
|
| Androstadienes | 2 | 1997 | 348 | 0.060 |
Why?
|
| Cell Movement | 3 | 2002 | 5200 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1999 | 1540 | 0.060 |
Why?
|
| Buprenorphine | 1 | 1993 | 656 | 0.060 |
Why?
|
| Aorta, Abdominal | 2 | 1987 | 625 | 0.060 |
Why?
|
| Systems Integration | 2 | 2004 | 426 | 0.060 |
Why?
|
| Sexual Behavior, Animal | 2 | 1996 | 120 | 0.060 |
Why?
|
| Infusions, Intravenous | 6 | 2000 | 2214 | 0.060 |
Why?
|
| Analysis of Variance | 5 | 2004 | 6224 | 0.060 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2004 | 18 | 0.060 |
Why?
|
| Species Specificity | 2 | 2004 | 2411 | 0.060 |
Why?
|
| Middle Aged | 36 | 2007 | 220584 | 0.060 |
Why?
|
| Iodobenzenes | 1 | 1983 | 23 | 0.060 |
Why?
|
| Thyroid Hormones | 1 | 1987 | 403 | 0.060 |
Why?
|
| Anticoagulants | 1 | 1999 | 4785 | 0.060 |
Why?
|
| Mice | 16 | 2004 | 81368 | 0.060 |
Why?
|
| Comorbidity | 3 | 2015 | 10505 | 0.060 |
Why?
|
| Reference Values | 5 | 1999 | 4919 | 0.050 |
Why?
|
| Transfection | 3 | 1999 | 5766 | 0.050 |
Why?
|
| Electrophoresis | 1 | 2002 | 226 | 0.050 |
Why?
|
| Adenosine Deaminase | 3 | 1994 | 251 | 0.050 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2003 | 370 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 1994 | 5780 | 0.050 |
Why?
|
| Cell Membrane | 9 | 1992 | 3680 | 0.050 |
Why?
|
| Exploratory Behavior | 1 | 2003 | 276 | 0.050 |
Why?
|
| Avoidance Learning | 1 | 2004 | 247 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1999 | 1517 | 0.050 |
Why?
|
| Aortic Aneurysm | 1 | 1987 | 648 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 1991 | 2160 | 0.050 |
Why?
|
| Guanine Nucleotides | 4 | 1983 | 55 | 0.050 |
Why?
|
| Prostaglandins | 1 | 2002 | 398 | 0.050 |
Why?
|
| DNA | 3 | 2002 | 7196 | 0.050 |
Why?
|
| Decerebrate State | 3 | 1992 | 42 | 0.050 |
Why?
|
| Dioxanes | 2 | 1981 | 36 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 1759 | 0.050 |
Why?
|
| Chronic Disease | 3 | 2013 | 9311 | 0.050 |
Why?
|
| Receptors, Prostaglandin E | 2 | 1992 | 56 | 0.050 |
Why?
|
| Aged | 22 | 2006 | 169042 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2004 | 537 | 0.050 |
Why?
|
| Myocardial Contraction | 4 | 1993 | 1515 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 1985 | 1056 | 0.050 |
Why?
|
| Dendrites | 1 | 2003 | 471 | 0.050 |
Why?
|
| Calmodulin | 2 | 1999 | 218 | 0.050 |
Why?
|
| Hormones | 1 | 1984 | 869 | 0.050 |
Why?
|
| Guanosine Triphosphate | 2 | 1981 | 316 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2002 | 596 | 0.040 |
Why?
|
| Receptors, Cell Surface | 2 | 1986 | 2802 | 0.040 |
Why?
|
| Trifluoperazine | 1 | 1999 | 37 | 0.040 |
Why?
|
| Dioxins | 1 | 1980 | 91 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 4947 | 0.040 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2002 | 393 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 1999 | 24 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 1986 | 1151 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 1989 | 1285 | 0.040 |
Why?
|
| Kidney Cortex | 1 | 1999 | 169 | 0.040 |
Why?
|
| Dexmedetomidine | 1 | 2004 | 317 | 0.040 |
Why?
|
| Bucladesine | 2 | 1991 | 118 | 0.040 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 1999 | 10 | 0.040 |
Why?
|
| Egtazic Acid | 1 | 1999 | 167 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2002 | 1646 | 0.040 |
Why?
|
| Point-of-Care Systems | 2 | 2006 | 1213 | 0.040 |
Why?
|
| Skin | 1 | 1993 | 4473 | 0.040 |
Why?
|
| Heart | 3 | 1993 | 4403 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 2000 | 1376 | 0.040 |
Why?
|
| Keratinocytes | 1 | 2002 | 790 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2005 | 2700 | 0.040 |
Why?
|
| Timolol | 2 | 1989 | 51 | 0.040 |
Why?
|
| Maleimides | 1 | 1998 | 112 | 0.040 |
Why?
|
| Mesocricetus | 2 | 1993 | 252 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4321 | 0.040 |
Why?
|
| Manganese | 1 | 1981 | 393 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2004 | 14389 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2015 | 4803 | 0.040 |
Why?
|
| Nicotinic Agonists | 1 | 2000 | 265 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 858 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 1169 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2007 | 1799 | 0.040 |
Why?
|
| Mitosis | 1 | 2002 | 1187 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1992 | 3415 | 0.040 |
Why?
|
| Time Factors | 9 | 1999 | 39913 | 0.040 |
Why?
|
| Calcimycin | 3 | 1994 | 213 | 0.030 |
Why?
|
| Enoxaparin | 1 | 1999 | 391 | 0.030 |
Why?
|
| Blotting, Western | 2 | 1996 | 5034 | 0.030 |
Why?
|
| Genes, jun | 1 | 1996 | 69 | 0.030 |
Why?
|
| Immediate-Early Proteins | 1 | 1999 | 444 | 0.030 |
Why?
|
| Quinpirole | 1 | 1996 | 32 | 0.030 |
Why?
|
| Adenosine Diphosphate Ribose | 2 | 1986 | 69 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1991 | 1738 | 0.030 |
Why?
|
| Exercise | 1 | 1993 | 5886 | 0.030 |
Why?
|
| Transducin | 1 | 1996 | 42 | 0.030 |
Why?
|
| Ergolines | 1 | 1996 | 57 | 0.030 |
Why?
|
| Blood Pressure Determination | 2 | 2007 | 633 | 0.030 |
Why?
|
| Neoplasm Transplantation | 3 | 1991 | 2010 | 0.030 |
Why?
|
| Dihydroalprenolol | 5 | 1983 | 8 | 0.030 |
Why?
|
| Body Weight | 5 | 1993 | 4614 | 0.030 |
Why?
|
| Injections, Intraventricular | 2 | 1996 | 225 | 0.030 |
Why?
|
| Isoquinolines | 2 | 1994 | 352 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2004 | 1872 | 0.030 |
Why?
|
| Chloroquine | 1 | 1997 | 274 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 618 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2000 | 1790 | 0.030 |
Why?
|
| Genitalia, Male | 1 | 1995 | 87 | 0.030 |
Why?
|
| Metoprolol | 1 | 1996 | 90 | 0.030 |
Why?
|
| 1-Sarcosine-8-Isoleucine Angiotensin II | 1 | 1995 | 3 | 0.030 |
Why?
|
| Allantois | 1 | 1995 | 33 | 0.030 |
Why?
|
| Spider Venoms | 1 | 1995 | 43 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3800 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4570 | 0.030 |
Why?
|
| Osmolar Concentration | 3 | 1999 | 659 | 0.030 |
Why?
|
| Organ Size | 2 | 1993 | 2252 | 0.030 |
Why?
|
| Terbutaline | 1 | 1995 | 23 | 0.030 |
Why?
|
| Imidazoles | 2 | 1999 | 1175 | 0.030 |
Why?
|
| Nicotine | 1 | 2000 | 679 | 0.030 |
Why?
|
| Reminder Systems | 3 | 2006 | 386 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 1995 | 13441 | 0.030 |
Why?
|
| Estrogens | 1 | 1981 | 1521 | 0.030 |
Why?
|
| Serine | 1 | 1998 | 830 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1996 | 309 | 0.030 |
Why?
|
| Medication Errors | 1 | 2001 | 783 | 0.030 |
Why?
|
| Brompheniramine | 1 | 1994 | 2 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 2 | 1999 | 361 | 0.030 |
Why?
|
| Emetine | 1 | 1993 | 15 | 0.030 |
Why?
|
| Artificial Intelligence | 3 | 2004 | 2574 | 0.030 |
Why?
|
| Anisomycin | 1 | 1993 | 27 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1996 | 380 | 0.030 |
Why?
|
| Situs Inversus | 1 | 1994 | 63 | 0.030 |
Why?
|
| Catalysis | 1 | 1996 | 773 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 1996 | 457 | 0.030 |
Why?
|
| Diphenhydramine | 1 | 1994 | 63 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1996 | 291 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1994 | 416 | 0.030 |
Why?
|
| Reflex | 1 | 1995 | 375 | 0.030 |
Why?
|
| Diet | 2 | 1999 | 8048 | 0.030 |
Why?
|
| Lipoprotein Lipase | 1 | 1994 | 133 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 1986 | 618 | 0.030 |
Why?
|
| Erythrocytes | 2 | 1981 | 2410 | 0.030 |
Why?
|
| Lovastatin | 1 | 1993 | 115 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1996 | 352 | 0.030 |
Why?
|
| Endomyocardial Fibrosis | 1 | 1993 | 41 | 0.030 |
Why?
|
| Primary Health Care | 3 | 2013 | 4668 | 0.030 |
Why?
|
| Choriocarcinoma | 1 | 1994 | 121 | 0.030 |
Why?
|
| Labetalol | 1 | 1993 | 29 | 0.030 |
Why?
|
| Dizocilpine Maleate | 1 | 1993 | 172 | 0.030 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1992 | 41 | 0.030 |
Why?
|
| Tritium | 4 | 1981 | 706 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1993 | 110 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2007 | 10199 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1994 | 661 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 1995 | 405 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2007 | 4007 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 1994 | 522 | 0.030 |
Why?
|
| Chlorpheniramine | 1 | 1992 | 13 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1900 | 0.030 |
Why?
|
| Forearm | 1 | 1995 | 427 | 0.030 |
Why?
|
| Aged, 80 and over | 7 | 1995 | 58894 | 0.030 |
Why?
|
| Endorphins | 1 | 1992 | 74 | 0.020 |
Why?
|
| Receptors, Opioid, delta | 1 | 1992 | 48 | 0.020 |
Why?
|
| Epoprostenol | 1 | 1993 | 247 | 0.020 |
Why?
|
| Smoking | 2 | 1999 | 9050 | 0.020 |
Why?
|
| Receptors, Opioid, mu | 1 | 1993 | 167 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 1963 | 0.020 |
Why?
|
| Free Radicals | 1 | 1992 | 238 | 0.020 |
Why?
|
| Ejaculation | 3 | 1996 | 59 | 0.020 |
Why?
|
| Adaptation, Biological | 1 | 1992 | 147 | 0.020 |
Why?
|
| Hemodynamics | 2 | 1995 | 4160 | 0.020 |
Why?
|
| Proteins | 1 | 1986 | 6030 | 0.020 |
Why?
|
| Prosencephalon | 1 | 1993 | 305 | 0.020 |
Why?
|
| Serotonin | 2 | 1986 | 1041 | 0.020 |
Why?
|
| DNA Replication | 1 | 1998 | 1414 | 0.020 |
Why?
|
| Collagen | 1 | 1999 | 2634 | 0.020 |
Why?
|
| Guanylate Cyclase | 1 | 1992 | 205 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 1993 | 565 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 3879 | 0.020 |
Why?
|
| DNA Primers | 1 | 1995 | 2817 | 0.020 |
Why?
|
| Indoles | 1 | 1998 | 1830 | 0.020 |
Why?
|
| Apolipoproteins A | 1 | 1990 | 95 | 0.020 |
Why?
|
| Antimalarials | 1 | 1997 | 907 | 0.020 |
Why?
|
| Temazepam | 1 | 1990 | 6 | 0.020 |
Why?
|
| Sensitivity and Specificity | 3 | 2002 | 14648 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 11069 | 0.020 |
Why?
|
| Dopamine | 2 | 1987 | 1606 | 0.020 |
Why?
|
| Tretinoin | 1 | 1993 | 519 | 0.020 |
Why?
|
| Embryo, Mammalian | 2 | 1994 | 1670 | 0.020 |
Why?
|
| Telemedicine | 1 | 2007 | 3050 | 0.020 |
Why?
|
| Cell Count | 1 | 1994 | 1835 | 0.020 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1989 | 48 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 1993 | 361 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1999 | 1977 | 0.020 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1992 | 269 | 0.020 |
Why?
|
| Ligands | 3 | 1982 | 3268 | 0.020 |
Why?
|
| Physical Fitness | 1 | 1993 | 743 | 0.020 |
Why?
|
| Hyperthyroidism | 2 | 1981 | 294 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1994 | 2668 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 1993 | 981 | 0.020 |
Why?
|
| Pharmacology, Clinical | 1 | 1987 | 22 | 0.020 |
Why?
|
| Practolol | 1 | 1987 | 3 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1993 | 874 | 0.020 |
Why?
|
| Chlorisondamine | 1 | 1987 | 2 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1994 | 2048 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2004 | 928 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1993 | 1594 | 0.020 |
Why?
|
| Streptozocin | 1 | 1988 | 193 | 0.020 |
Why?
|
| Triiodothyronine | 2 | 1987 | 493 | 0.020 |
Why?
|
| Hydralazine | 1 | 1987 | 34 | 0.020 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1991 | 702 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 1997 | 1365 | 0.020 |
Why?
|
| Methods | 1 | 1987 | 1065 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 1992 | 1152 | 0.020 |
Why?
|
| 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone | 1 | 1986 | 7 | 0.020 |
Why?
|
| Behavior Control | 1 | 2007 | 47 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 1999 | 2569 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 1990 | 397 | 0.020 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1986 | 58 | 0.020 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1986 | 65 | 0.020 |
Why?
|
| Piperazines | 2 | 1994 | 2521 | 0.020 |
Why?
|
| Administration, Oral | 3 | 1999 | 4010 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1998 | 2056 | 0.020 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2000 | 1875 | 0.020 |
Why?
|
| Scopolamine | 1 | 1986 | 93 | 0.020 |
Why?
|
| Respiration | 1 | 1993 | 1656 | 0.020 |
Why?
|
| Copulation | 2 | 1996 | 12 | 0.020 |
Why?
|
| Cattle | 1 | 1992 | 3841 | 0.020 |
Why?
|
| Hypertrophy | 1 | 1988 | 560 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 1986 | 201 | 0.020 |
Why?
|
| Depression, Chemical | 2 | 1995 | 184 | 0.020 |
Why?
|
| Plasmids | 1 | 1991 | 2265 | 0.020 |
Why?
|
| Hypothyroidism | 2 | 1981 | 667 | 0.020 |
Why?
|
| Lipase | 1 | 1988 | 324 | 0.020 |
Why?
|
| Software | 1 | 2000 | 4431 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2002 | 7847 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1988 | 586 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1992 | 2231 | 0.020 |
Why?
|
| Atropine | 1 | 1986 | 244 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2002 | 12116 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1998 | 0.020 |
Why?
|
| Functional Laterality | 1 | 1992 | 2256 | 0.020 |
Why?
|
| Hypophysectomy | 1 | 1985 | 114 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1991 | 1524 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 22115 | 0.020 |
Why?
|
| Chemistry | 2 | 1987 | 346 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 1985 | 224 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1992 | 6338 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 1987 | 590 | 0.010 |
Why?
|
| Chemical Phenomena | 2 | 1987 | 506 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1989 | 2261 | 0.010 |
Why?
|
| Area Under Curve | 2 | 1999 | 1635 | 0.010 |
Why?
|
| Structure-Activity Relationship | 5 | 1992 | 3074 | 0.010 |
Why?
|
| Naloxone | 1 | 1987 | 370 | 0.010 |
Why?
|
| Stereoisomerism | 2 | 1995 | 613 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1986 | 629 | 0.010 |
Why?
|
| Heart Failure | 1 | 1988 | 11669 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1987 | 15612 | 0.010 |
Why?
|
| Affect | 1 | 1992 | 1486 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1985 | 252 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1986 | 2185 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1990 | 1810 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1989 | 891 | 0.010 |
Why?
|
| Sample Size | 1 | 2007 | 838 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1991 | 1947 | 0.010 |
Why?
|
| Physicians, Family | 1 | 2006 | 348 | 0.010 |
Why?
|
| Glucagon | 1 | 1986 | 531 | 0.010 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 1983 | 114 | 0.010 |
Why?
|
| Geriatrics | 1 | 1987 | 386 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 1993 | 2187 | 0.010 |
Why?
|
| Adrenalectomy | 2 | 1987 | 346 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1999 | 5672 | 0.010 |
Why?
|
| Cross-Over Studies | 2 | 1999 | 2079 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1993 | 2110 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1991 | 4804 | 0.010 |
Why?
|
| NAD | 1 | 1986 | 614 | 0.010 |
Why?
|
| Reproducibility of Results | 2 | 2000 | 20074 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1985 | 635 | 0.010 |
Why?
|
| Feedback | 1 | 2006 | 790 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1994 | 2533 | 0.010 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 5835 | 0.010 |
Why?
|
| Phospholipids | 1 | 1985 | 786 | 0.010 |
Why?
|
| Alprenolol | 1 | 1981 | 8 | 0.010 |
Why?
|
| Lung | 3 | 1992 | 9998 | 0.010 |
Why?
|
| Mutation | 2 | 1999 | 30016 | 0.010 |
Why?
|
| Uterine Contraction | 1 | 1981 | 91 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1986 | 1182 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 3451 | 0.010 |
Why?
|
| Estrone | 1 | 1981 | 234 | 0.010 |
Why?
|
| Organ Culture Techniques | 2 | 1994 | 794 | 0.010 |
Why?
|
| Hippocampus | 1 | 1993 | 3761 | 0.010 |
Why?
|
| Kidney | 1 | 1996 | 7045 | 0.010 |
Why?
|
| Oxygen | 1 | 1992 | 4226 | 0.010 |
Why?
|
| Turkeys | 1 | 1979 | 44 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2007 | 1403 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1983 | 1972 | 0.010 |
Why?
|
| Early Growth Response Protein 1 | 1 | 1999 | 133 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2002 | 395 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1992 | 5110 | 0.010 |
Why?
|
| Algorithms | 1 | 2000 | 14018 | 0.010 |
Why?
|
| Ions | 1 | 1980 | 256 | 0.010 |
Why?
|
| Disease Models, Animal | 3 | 1988 | 18221 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 1987 | 1115 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1987 | 1896 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 3410 | 0.010 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1987 | 1310 | 0.010 |
Why?
|
| Genes, myc | 1 | 1999 | 390 | 0.010 |
Why?
|
| Biological Availability | 1 | 1999 | 389 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 1242 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 521 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1988 | 6305 | 0.010 |
Why?
|
| California | 1 | 2002 | 1430 | 0.010 |
Why?
|
| Computers | 1 | 1980 | 591 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1999 | 725 | 0.010 |
Why?
|
| Protein Binding | 2 | 1980 | 9345 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1993 | 4642 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2002 | 1155 | 0.010 |
Why?
|
| Histamine Antagonists | 1 | 1997 | 92 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2002 | 770 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1992 | 6561 | 0.010 |
Why?
|
| Energy Intake | 1 | 1984 | 2132 | 0.010 |
Why?
|
| Cholesterol | 1 | 1985 | 2903 | 0.010 |
Why?
|
| omega-Agatoxin IVA | 1 | 1995 | 18 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 1483 | 0.010 |
Why?
|
| Positive-Pressure Respiration | 1 | 2000 | 638 | 0.010 |
Why?
|
| Health Behavior | 1 | 2007 | 2643 | 0.010 |
Why?
|
| Penile Erection | 1 | 1995 | 101 | 0.010 |
Why?
|
| Sodium | 1 | 1980 | 1588 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 11514 | 0.010 |
Why?
|
| Binding Sites | 1 | 1984 | 6051 | 0.010 |
Why?
|
| Safety Management | 1 | 2001 | 760 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 1988 | 3085 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2002 | 1315 | 0.010 |
Why?
|
| Leukocytes | 1 | 1983 | 2023 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1697 | 0.010 |
Why?
|
| Cognition | 1 | 1992 | 6987 | 0.010 |
Why?
|
| Models, Biological | 2 | 1981 | 9461 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2002 | 821 | 0.010 |
Why?
|
| Disease | 1 | 1980 | 670 | 0.010 |
Why?
|
| Melanoma | 1 | 1993 | 5697 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1995 | 420 | 0.010 |
Why?
|
| Neurons | 1 | 1993 | 9438 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1993 | 4845 | 0.010 |
Why?
|
| Double-Blind Method | 3 | 1993 | 12334 | 0.010 |
Why?
|
| Brain | 2 | 1996 | 27101 | 0.010 |
Why?
|
| Coronary Disease | 1 | 1987 | 5912 | 0.010 |
Why?
|
| United States | 4 | 2004 | 72272 | 0.010 |
Why?
|
| Medetomidine | 1 | 1992 | 4 | 0.010 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1992 | 2 | 0.010 |
Why?
|
| Reperfusion | 1 | 1993 | 271 | 0.010 |
Why?
|
| Aminophylline | 1 | 1992 | 41 | 0.010 |
Why?
|
| Isomerism | 1 | 1992 | 197 | 0.010 |
Why?
|
| Glutamates | 1 | 1993 | 389 | 0.010 |
Why?
|
| Enkephalins | 1 | 1992 | 139 | 0.010 |
Why?
|
| Risk Factors | 2 | 1989 | 74115 | 0.010 |
Why?
|
| Pyramidal Tracts | 1 | 1993 | 251 | 0.010 |
Why?
|
| Research Design | 1 | 2007 | 6174 | 0.010 |
Why?
|
| Veterans | 1 | 2004 | 2649 | 0.010 |
Why?
|
| Administration, Sublingual | 1 | 1989 | 59 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 13245 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1985 | 12966 | 0.010 |
Why?
|
| Cell Survival | 1 | 1999 | 5780 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 641 | 0.010 |
Why?
|
| Apolipoprotein A-I | 1 | 1990 | 299 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2002 | 2778 | 0.000 |
Why?
|
| Pulse | 1 | 1988 | 217 | 0.000 |
Why?
|
| GTP Phosphohydrolases | 1 | 1992 | 517 | 0.000 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 1989 | 116 | 0.000 |
Why?
|
| Random Allocation | 1 | 1992 | 2392 | 0.000 |
Why?
|
| Lactates | 1 | 1989 | 404 | 0.000 |
Why?
|
| Sympathectomy, Chemical | 1 | 1987 | 25 | 0.000 |
Why?
|
| Adolescent | 3 | 1992 | 88234 | 0.000 |
Why?
|
| Glutamic Acid | 1 | 1993 | 1175 | 0.000 |
Why?
|
| Administration, Cutaneous | 1 | 1989 | 712 | 0.000 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 3204 | 0.000 |
Why?
|
| Angiotensins | 1 | 1987 | 142 | 0.000 |
Why?
|
| Glucose Tolerance Test | 1 | 1989 | 1178 | 0.000 |
Why?
|
| Receptor, Insulin | 1 | 1989 | 836 | 0.000 |
Why?
|
| Posture | 1 | 1990 | 956 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1985 | 137 | 0.000 |
Why?
|
| Biological Transport | 1 | 1989 | 2089 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1992 | 3965 | 0.000 |
Why?
|
| Asthma | 1 | 1983 | 6233 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6074 | 0.000 |
Why?
|
| Lactic Acid | 1 | 1989 | 1139 | 0.000 |
Why?
|
| Carboxylic Acids | 1 | 1983 | 90 | 0.000 |
Why?
|
| Airway Resistance | 1 | 1983 | 406 | 0.000 |
Why?
|
| Pregnancy | 2 | 1995 | 29868 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1993 | 4242 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1999 | 9172 | 0.000 |
Why?
|
| Electric Stimulation | 1 | 1987 | 1734 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 9586 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1983 | 1310 | 0.000 |
Why?
|
| Digitonin | 1 | 1981 | 26 | 0.000 |
Why?
|
| Ranidae | 1 | 1981 | 32 | 0.000 |
Why?
|
| Amides | 1 | 1983 | 449 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 2002 | 26049 | 0.000 |
Why?
|
| Epididymis | 1 | 1981 | 227 | 0.000 |
Why?
|
| Iodine | 1 | 1981 | 287 | 0.000 |
Why?
|
| Prognosis | 1 | 2000 | 29600 | 0.000 |
Why?
|
| Dogs | 1 | 1983 | 3838 | 0.000 |
Why?
|
| Genotype | 1 | 1993 | 12978 | 0.000 |
Why?
|
| Homeostasis | 1 | 1989 | 3321 | 0.000 |
Why?
|
| Prospective Studies | 2 | 1993 | 54360 | 0.000 |
Why?
|
| Mass Spectrometry | 1 | 1985 | 2189 | 0.000 |
Why?
|
| Lipids | 1 | 1989 | 3332 | 0.000 |
Why?
|
| Thyroid Gland | 1 | 1981 | 1170 | 0.000 |
Why?
|
| Age Factors | 1 | 1992 | 18381 | 0.000 |
Why?
|
| Anesthesia | 1 | 1985 | 1591 | 0.000 |
Why?
|
| Obesity | 1 | 1981 | 12933 | 0.000 |
Why?
|